

The Anti-Diabetic Potential Of Mushrooms: A Review

Waill Elkhateeb¹, Galappaththi MCA², Dina E. El-Ghwas^{1*}, Ghoson Daba¹

¹Chemistry of Natural and Microbial Products Department, Pharmaceutical Industries institute, National Research Centre, Dokki, Giza, 12622, Egypt.

²Postgraduate Institute of Science (PGIS), University of Peradeniya, Peradeniya, Sri Lanka.
Correspondence author: dinaelghwas7781@yahoo.com

Abstract

Diabetes is emerging as a pandemic, so it is essential to find new nutraceuticals or drugs to treat or prevent it. Some mushrooms appear to be effective in controlling blood glucose levels and correcting diabetes problems without any negative side effects. Mushrooms with immune-modulating polysaccharides are used in limited areas as palatable food or health-promoting dietary supplements or medicine. However, to date, scientific or clinical research on mushrooms has not been sufficient to allow them to be used as recognized medicines or nutraceuticals worldwide. These functional fungi may have a greater impact on the prevention and treatment of diabetes. Therefore, further studies are needed to identify their active compounds for improving diabetes drugs or nutraceuticals. This review focuses on prospective mushrooms that have demonstrated anti-diabetic effects in clinical or experimental studies and prevent or slow the progression of diabetes mellitus

Keywords: Biological activities; Fungi; Medicinal mushrooms; Secondary metabolites

Introduction

Many researchers are interested in the use of microbial secondary metabolites

normally, and mushroom metabolites in particular in various fields of biotechnology, due to the bioactive properties of these metabolites, which have led to their use in pharmaceutical, industrial, and agricultural fields. Diabetes is a serious health problem that predisposes to noticeably increase. Despite numerous prevention strategies and a range of drugs, the treatment of diabetes remains largely unsatisfactory (1). Diabetes is one of the prominent public health problems at present. Lifestyle changes directly relate to this problem (2). Most of the chronic complications of diabetes are micro- and macrovascular diseases resulting from established hyperglycemic conditions. After the failure of the first-choice therapy, which is based on dietary modification and exercise, conventional treatment using anti-hyperglycemic substances with different mechanisms of action is used for type II diabetes in modern medicine (3). Abou Zaid et al. (2017) and Elkhateeb et al (2021a) defined the mushrooms as macro-fungi with prominent fruiting bodies that may be hypogeous or epigeous, large enough to be seen with naked eyes and to be picked by hand (4-5). Mushrooms were valued as palatable foods and as medicinal substances. Mushrooms are also considered functional foods for their bioactive compounds that have multiple beneficial effects on human health

(6). Diabetes mellitus is a metabolic disorder shown by high blood glucose levels. It is indicated by insulin insufficiency, receptor, or dysfunction that causes increased blood glucose levels and metabolic problems. Polysaccharides, proteins, fibers, and many other biomolecules isolated from mushrooms have been exhibited to be beneficial in the treatment of diabetes as biological anti-hyperglycemic drugs (7). Studies have shown that mushrooms display anti-diabetic properties, including antioxidant, blood glucose level reduction, insulin secretion through glucose stimulation, digestive enzymes, and inhibitory effects on tyrosine kinase (8-16). Mushrooms in the phyla *Ascomycota* and *Basidiomycota* are much admired for their nutritional value and pharmacological properties. In traditional medicine, they have long been used to maintain health, and prevent and treat various human diseases. Many studies have documented the beneficial effects of medicinal mushrooms in the treatment of diabetes (17-21). However, scientific evidence is insufficient to conclude the effectiveness of individual medicinal mushrooms. Mushrooms belong to the genera *Ganoderma* (*G. lucidum*), *Auricularia* (*A. auricula-judae*), *Inonotus* (*I. obliquus*), *Morchella* (*M. conica*), *Coprinus* (*C. comatus*), *Tremella* (*T. fuciformis*), *Laetiporus* (*L. sulphurous*), *Lentinula* (*L. edodes*), *Agaricus* (*A. blazei*), *Lignosus* (*L. rhinocerotis*), *Grifola frondosa* and *Phellinus* (*P. linteus*, *P. ribis*, *P. rimosus* and *P. igniarius*) have shown considerable hypoglycemic effect in experimental diabetic models (3, 6, 20, 22). This review focuses on mushrooms' antidiabetic effects and potential mechanisms of action in both in vitro and in vivo studies. Prospects in this field of research and limitations that may affect the development of potential drugs in mushrooms are also being considered.

Gill mushrooms (*Agaricus* and *Coprinus*)

The genus *Agaricus* is the most cultivated edible mushroom in the world (Figure 1). It contains bioactive compounds that may have valuable effects on patients with diabetes mellitus (23-25). *Agaricus bisporus* (white button

mushroom) contains high amounts of dietary fibers and antioxidants, including vitamin C, D, and B12; folates; and polyphenols which may have beneficial effects on cardiovascular and diabetic diseases (24). Ekowati et al. (2018) determined the effects of *A. bisporus* administration on the blood glucose, and malondyaldehyde levels as well as superoxide dismutase activity of alloxan-induced diabetic rats and showed that *A. bisporus* extract could lower blood glucose levels and malondyaldehyde and also increase superoxide dismutase (26). *A. bisporus* extract can be used as an alternative natural anti-diabetic agent and can be applied easily and on a more controlled industrial scale in the community (26). Abou Zaid et al. (2017) concluded that, *A. bisporus* has an anti-diabetic effect against streptozotocin-induced pancreatic islet damage (4). In addition, repair/regeneration of β -cells in the islets of Langerhans and induce insulin synthesis and secretion. The therapeutic effects of *A. bisporus* are dependent on its anti-oxidant properties and improving the action of the anti-oxidant system against the oxidative stress of Streptozotocin and its harmful effect.

Coprinus is also called shaggy mane, shaggy ink cap, chicken drumstick mushroom, or lawyer's wig. In Asian countries, *Coprinus comatus* is approved as an edible mushroom and is often cultivated for consumption, while in many other countries, although it is widespread, it is not recognized and not used (Figure 1). Various studies have shown many biological activities of *C. comatus*, including anti-diabetic, anti-cancer, anti-oxidant hepatoprotective, anti-inflammatory, anti-obesity, anti-bacterial, anti-androgenic, anti-fungal, anti-nematode, and anti-viral (15). *C. comatus* is a nutritious and delicious edible mushroom that is also highly valuable due to its physiological benefits. It has been reported to have anti-diabetes, anti-tumor, and anti-mutagen properties and to protect the liver from damage (27-30). Also, Ding et al. (2010) reported that, *C. comatus* declined blood glucose levels and enhanced glucose tolerance in normal mice due to a diet containing 33.3%

(w/w) dried fruiting bodies of *C. comatus*, and it had a slowly developed, mild hypoglycaemic condition on normal mice (27).

Ganoderma is a fungus that causes a wood rot infection through tree injuries. It strikes large roots and the base of the trunk but can expand several feet. *Ganoderma* is a rot fungus widely distributed in Asian countries, and many species are used as tonics to increase longevity and health (31) as illustrated at Figure 2. *G. lucidum* extracts have been identified as a possible supplemental treatment for diabetes. Polysaccharides, proteins, proteoglycans, and triterpenoids of *G. lucidum* have been shown hypoglycemic effects (32-33). *G. lucidum* polysaccharides have been shown hypoglycemic activity by decreasing plasma sugar levels and increasing plasma insulin levels in mice. Protein tyrosine phosphatase 1B is a good therapeutic target in diabetes, and *G. lucidum* proteoglycan can hinder this enzyme *in vitro*. Also, *G. lucidum* triterpenoids have exhibited an inhibitory effect on aldose reductase and α -glucosidase, which can suppress postprandial hyperglycemia (34). Jung et al. (2005) reported that, the bioactive polysaccharide components of *G. applanatum* are responsible for anti-diabetic properties (35).

Grifola frondosa (Maitake), belonging to phylum: *Basidiomycota*, class: *Agaricomycetes*, order: *Polyporales*, and family: *Meripilaceae* (Figure 2) has been verified to possess substances with anti-diabetic activity. When 1 g/d of powdered fruit body of maitake was administered orally to a genetically diabetic mouse (KK-Ay), a decrease in blood glucose was observed, in contrast to the control group. In addition, plasma insulin and triglyceride levels showed a similar change to blood glucose levels when maitake was administered (36). *Grifola frondosa*, a high-value medicinal mushroom, is popularly consumed as traditional medicine and health food in China and Japan. It is an herbal medicine traditionally used to treat inflammation, cancer and diabetes (37). Kou et al. (2019) also indicated that *G. frondosa* polysaccharides

exhibited hypoglycemic activities against diabetic rats (38).

In the last decade, several investigations have documented the biological activities of *Inonotus obliquus* fruiting bodies, such as anti-cancer, anti-oxidation, anti-inflammatory, anti-diabetic and immune-enhancing activities (4, 39-40) (Figure 2). The medicinal benefits of *I. obliquus*, known as 'Chaga' have recently been demonstrated with strong anti-cancer, anti-oxidation, anti-inflammatory and anti-diabetic effects (13). Extracts of Chaga (*I. obliquus*) act as an anti-diabetic by lowering blood glucose levels. Polysaccharides are one of the main components of Chaga extracts, are able to inhibit α -glucosidase, an enzyme that hydrolyzes carbohydrates. Thus, Chaga extracts act as a hypoglycemic agent by slowing glucose uptake in the digestive tract, thereby preventing hyperglycemia (41-42). Sun et al. (2008) and Thomas et al. (2020) reported that polysaccharides of *I. obliquus* are capable of lowering the level of glucose triglycerides, fatty acids, and cholesterol levels in the blood (43, 13). *Laetiporus sulphureus* species commonly known as sulfur shelf, sulfur polypore, or chicken of the woods. It is an edible wood-rotting basidiomycete fungus belonging to the family *Polyporaceae* (Figure 2). It is widespread in Europe, Asia, and North America. This fungus is commonly found on hardwoods or conifers. *L. sulphureus* can be easily recognized by its striking yellowish or orange-coloured shelf-like fruit bodies. It is also easily recognized in forests and urban areas due to its impressive size (up to 40 cm wide) and brilliant bright sulfur yellow to orange coloured porous basidiocarps. *L. sulphureus* species is rich in several bioactive compounds such as polysaccharides, triterpenes, laetiporic acids, lectins, α -glucans, and phenolic compounds. Unlike other polypores, *L. sulphureus* has a long consumption history, especially in Thailand, North America and Japan. Additionally, this fungus has long been used in Asian herbal medicine and is also known as a source of anti-diabetic, anti-oxidant, anti-tumor, anti-viral,

anti-inflammatory, anti-coagulant, anti-bacterial and other properties (15, 44).

The mushroom *Lignosus rhinocerotis*, belonging to phylum: *Basidiomycota*, class: *Agaricomycetes*, order: *Polyporales*; and family: *Polyporaceae*, which is native to tropical regions such as Malaysia, Indonesia, and the Philippines (Figure 2), contains a very large amount of potential anti-oxidants and anti-diabetic agents. Biological compounds present in the freeze-dried *L. rhinocerotis* powder have been found to exhibit anti-diabetic properties by significantly reducing elevated blood glucose concentrations to a normal range (Nyam et al. 2017, Ganesan & Xu 2019). *Phellinus* mushroom, known as “Sanghuang” in China, is a valuable functional mushroom that has been considered a food source for centuries in several East Asian countries, including China, Korea, and Japan (Figure 2). *P. baumii* has a wide range of biological activities, such as blood lipid-lowering, anti-tumor, anti-influenza, anti-oxidation abilities, and blood sugar regulation (45). Earlier studies have revealed that extracts and some phenolic compounds from the wild *Phellinus* show a hypoglycemic effect. Phenolic compounds isolated from the fruit body of wild *Phellinus* have been shown to exhibit a hypoglycemic effect; they consist of hispidin, chlorophellins C, gilvsins A, B, C, D, 7,8-dihydroxycoumarin, 3,4-dihydroxybenzalacetone, 7,3'-dihydroxy-5'-methoxyiso-flavone, and inoscavin C (46-47).

In the previous studies by Yang et al. (2020), and Jang et al. (2010), the fruit body of wild *P. baumii* has been reported to alleviate diabetes, and antioxidants are beneficial to diabetes by protecting the β -cell from damage due to oxidative stress (46, 48). The cultivated *P. baumii* fruit body was extracted with 80% ethanol extracts, and different fractions were obtained using petroleum ether, ethyl acetate (EtOAc), n-butanol (n-BuOH), and water. The results revealed that the ethyl acetate fraction showed the highest inhibitory effect on α -glucosidase activity, which was higher than the positive control. It was composed mainly of phenolic

compounds with a purity of 79.45% and characterized by liquid chromatography-mass spectrometry as osmudacetone, hispidin, davallialactone, 2,5-bis(4,7-dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl) cyclohexa-2,5-diene-1,4-dione, hypholomin B, and inoscavin A. Furthermore, the ethyl acetate fraction increased the glucose consumption of insulin-resistant HepG2 cells. The ethyl acetate fraction also demonstrated antioxidant activities by scavenging 1,1-diphenyl-2-picrylhydrazyl, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic) diammonium salt, and hydroxyl radicals. The ethyl acetate fraction of the cultivated *P. baumii* fruit body had significant anti-diabetic effects, probably due to the high content of selective phenolic compounds. Thus, the cultivated fruit body of *P. baumii* can be a sustainable source for the treatment of diabetes (48).

Jelly mushrooms (*Auricularia* and *Tremella*)

Auricularia auricula-judae or commonly known Judas's ear or the jelly ear fungus, is an edible mushroom characterized by its brownish, ear-like jelly shape. *A. auricula-judae* fruit body consists of a high content of carbohydrates, protein, and minerals such as calcium, phosphorus, potassium, and iron. *Auricularia* species are widely investigated due to medicinal biological activities exerted by their extracted compounds (20). Fruit bodies of *A. auricula-judae* grow on wood and are commonly used as food and as anti-diabetic, anti-hypertensive, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial drugs in many Asian countries (Figure 3). *A. auricula-judae* has been commercialized in industry and represents a promising source for new chemical compounds with different biological functions (13, 20). *Tremella* is a genus of fungi belonging to Division; Basidiomycota, Class; Tremellomycetes, Order; Tremellales, Family; Tremellaceae. Basidiocarps are gelatinous and described as jelly fungi (Figure 3). *Tremella* species grow mainly on wood rotting. Some species of *Tremella* parasitize the fruiting bodies of their hosts (fun-

gal hosts) and are sometimes attached to the host's hyphae, and others to wood mycelium. *Tremella* species occur worldwide as a group. Currently, more than 100 species of *Tremella* are identified worldwide. *Tremella fuciformis*, and *Tremella aurantialba* are cultivated commercially for food and medicinal purposes (4). Exo-polysaccharides from *T. fuciformis* may be beneficial for the fight against type 1 diabetes mellitus. When the blood glucose level is higher than exo-polysaccharides from *T. fuciformis* the lowering effect is not fast and the function is not satisfactory (49). Kiho et al. (2001) reported that continuous oral administration of a solution of acidic polysaccharide (TAP) (0.5 g/l) and TAP-H solution (degradation products of TAP) (1.5 g/l) reduced plasma glucose levels in diabetes and that demonstrated by using KK-Ay mice (non-insulin dependent diabetes) (50). TAP and TAP-H significantly reduced insulin, total cholesterol, and triglyceride levels in the blood of the mice. In fecal excretion, TAP and TAP-H significantly increased the total bile acid, while the cholesterol content of both groups was lower than the control. In addition, TAP and TAP-H significantly reduced the plasma lipoperoxide level. A study shows that TAP and TAP-H have an anti-diabetic effect in a diabetes model mouse (50).

Other mushrooms (*Morchella*, *Cordyceps*)

Ascomycetes inhabit a wide range of ecological niches, perform vital ecosystem roles, particularly in carbon cycling and serve as symbiotic partners with several tree species. Most ascomycetes are usually associated with plants as pathogens or decomposers. Ascomycetes mushrooms are known for their use as a source of food and therapeutic bioactive compounds, such as *Morchella*. *Morchella* is one of the most economically beneficial and edible wild mushrooms (Figure 4). It has several common names, such as guchi, morel, yellow morel, sponge morel, common morel, true morel, morel mushroom and so on. *Morchella* has nutritional and medicinal values due to its unique bioactive compounds, such as fibers, vitamins, polysaccharides, proteins, and trace elements

(4, 51). *Morchella conica* is an edible mushroom that exhibits anti-diabetic properties. It showed controlled hyperglycemic index is an alteration of PTP1B protein indication in the liver and pancreas. *Morchella conica* is a potential source of treatment for diabetes mellitus, involved in reducing elevated blood glucose levels during diabetes, which is further studied with oral hypoglycemic therapy (52).

Elkhateeb et al. (2019) documented that, the polysaccharides of *Cordyceps sinensis* and *Cordyceps militaris* (insect pathogen mushrooms), represent the major existing compounds and exhibit anti-diabetic, anti-oxidant, anti-inflammatory, anti-cancer, anti-microbial activities (6). *Cordyceps sinensis* and *C. militaris* extracts are safe pharmacological agents with good anti-diabetic and anti-nephropathic properties and have great potential as a new source of diabetes treatment (53) (Figure 4). *Cordyceps militaris* extracts revealed a considerable decline in blood glucose levels by enabling glucose metabolism and strongly suppressed total cholesterol and triglycerides concentration in serum. Extracts of *C. militaris* exhibit anti-oxidative activity, as evidenced by normalized levels of superoxide dismutase and glutathione peroxidase. Inhibitory effects on blood urea nitrogen, creatinine, uric acid, and protein demonstrated the protection of *C. militaris* extracts against diabetic nephropathy (54-55).

Prospects of developing medicinal mushrooms for clinical trials in patients with diabetes

Currently, the enormous potential of mushrooms for treating diabetes has been studied. However, there are many unknowns and limitations in the application of fungal bioactive compounds in diabetic patients. Currently, most studies focus on polysaccharide-enriched fractions or crude mushroom extract. A relatively limited number of studies have also been conducted on several species of mushrooms that are used as medicines for patients with type 2 diabetes. Therefore, further studies are needed

to investigate the treatment of type 2 diabetes and the pure compounds and their therapeutic potential in diabetic patients by mushroom (56).

Conclusion

Medicinal mushrooms represented by *Ganoderma applanatum* and *Ganoderma lucidum*, *Cordyceps sinensis* and *Cordyceps militaris*, *Auricularia auricula-judae*, *Inonotus obliquus*, *Morchella*, *Coprinus*, *Laetiporus*, *Tremella*, *Agaricus*, *Phellinus*, *Grifola frondosa* and *Lignosus rhinocerotis* have been recommended as a source of natural biologically active compounds and have been targeted as potential hypoglycemic and anti-diabetic agents since ancient times. Polysaccharides, proteins, dietary fibers, and other bioactive compounds isolated from edible mushrooms have been shown to lower blood sugar levels in both in vivo and in vitro models. Currently, significant studies have been conducted to investigate the mechanisms of hypoglycemic activities of mushrooms, and a large number of triterpenes and polysaccharides have been extracted from them. However, it is important to isolate and identify bioactive compounds with anti-diabetic potential from multiple mushroom species. Future investigations and further research are needed for bio prospect new medicinal and edible mushrooms for anti-diabetic efficacy and subsequent isolation of active biomolecules.

Acknowledgments

The authors acknowledge the National Research Centre (NRC) of Egypt for providing all needed facilities and logistics for the study.

References

1. Perera, P. K. and Li, Y. (2011). Mushrooms as a functional food mediator in preventing and ameliorating diabetes. *Functional foods in health and disease*, 1(4):161–171.]
2. Zimmet, P. Z., Magliano, D. J., Herman, W. H. and Shaw, J. E. (2014). Diabetes: a 21st century challenge. *The lancet Diabetes & endocrinology*. 2(1): 56.
3. Ajith, T. A. and Janardhanan, K. K. (2021). Antidiabetic Properties of Medicinal Mushrooms with Special Reference to *Phellinus* Species: A Review. *The Natural Products Journal*, 11(2): 120 - 126.]
4. Abou Zaid, O. A., Sonbaty, S. E. and Nema, M. A. (2017). Anti-diabetic activity of *Agaricus bisporus*: A biochemical and pathological study.] *International Journal of Pharma Sciences*, 7 (2): 1740 - 1745.
5. Elkhateeb, W., Thomas, P., Elnahas, M., Daba, G. (2021a). Hypogeous and Epigeous Mushrooms in Human Health. In: *Advances in Macrofungi*, CRC Press. 7–19.
6. Elkhateeb, W. A., Daba, G. M., Thomas, P. W., Wen, T. C. (2019). Medicinal mushrooms as a new source of natural therapeutic bioactive compounds. *Egypt Pharmaceu J.* 18(2): 88–101.]
7. Daba, G. M., Elkhateeb, W., ELDien, A. N., Fadl, E., Elhagrasi, A., Fayad, W., Wen, T. C. (2020). Therapeutic potentials of n-hexane extracts of the three medicinal mushrooms regarding their anti-colon cancer, antioxidant, and hypocholesterolaemia capabilities. *Biodiversitas Journal of Biological Diversity*, 21(6): 1-10.]
8. Du, B. and Xu, B. (2014). An insight into anti-diabetic effects of mushrooms. In: Pesti G (Eds.), *Mushrooms: Cultivation, antioxidant properties and health benefits*. New York: Nova Science Publishers. 141-155.]
9. Daba, G. and Elkhateeb, W. A. (2020). The endless nutritional and pharmaceutical benefits of the Himalayan gold, *Cordyceps*; Current knowledge and prospective potentials. *Asian Journal of Natural Prod-*

- uct Biochemistry, 18(2):1- 8
10. Elkhateeb, W. A. (2020). What medicinal mushroom can do. *Chemistry Research Journal* 5(1), 106–118.
 11. Elkhateeb, W. A., Daba, G. M., El-Dein, A. N, Sheir, D. H., Fayad, W., Shaheen, M. N. and Wen, T. C. (2020). Insights into the in-vitro hypocholesterolaemia, antioxidant, antirotavirus, and anticolon cancer activities of the methanolic extracts of a Japanese lichen, *Candelariella vitellina*, and a Japanese mushroom, *Ganoderma applanatum*. *Egyptian Pharmaceutical Journal*, 19(1): 67
 12. Elkhateeb, W. A. and Daba, G. (2020). The endless nutritional and pharmaceutical benefits of the Himalayan gold, Cordyceps; Current knowledge and prospective potentials Biofarmasi. *Journal of Natural Product Biochemistry*, 18(2): 70–77.
 13. Thomas, P. W., Elkhateeb, W. A. and Daba, G. M. (2020). Chaga (*Inonotus obliquus*): A medical marvel but a conservation dilemma. *Sydowia* 72: 123–130
 14. Elkhateeb, W. A., El Ghwas, D. E., Gundaju, N. R., Somasekhar, T., Akram, M. and Daba, G. M. (2021b). Chicken of the Woods *Laetiporus Sulphureus* and *Schizophyllum Commune* Treasure of Medicinal Mushrooms. *Open Access Journal of Microbiology & Biotechnology*. 6(3): 1–7.
 15. Elkhateeb, W. A. and Daba, G. M. (2021a). Highlights on the Golden Mushroom *Cantharellus cibarius* and unique Shaggy ink cap Mushroom *Coprinus comatus* and Smoky Bracket Mushroom *Bjerkandera adusta* Ecology and Biological Activities. *Open Access Journal of Mycology & Mycological Sciences*, 4(2): 1–8.
 16. Elkhateeb, W. A. and Daba, G. M. (2021b). Mycotherapy of the good and the tasty medicinal mushrooms *Lentinus*, *Pleurotus*, and *Tremella*. *Journal of Pharmaceutics and Pharmacology Research*, 4(3): 1– 6.
 17. De Silva, D. D., Rapior, S., Hyde, K. D. and Bahkali, A. H. (2012). Medicinal mushrooms in prevention and control of diabetes mellitus. *Fungal Diversity*. 56(1): 1–29
 18. Patel, Y., Naraian, R. and Singh, V. K. (2012). Medicinal properties of Pleurotus species (oyster mushroom): a review. *World Journal of Fungal and Plant Biology*, 3(1): 1–12
 19. Friedman, M. (2016). Mushroom polysaccharides: chemistry and antiobesity, antidiabetes, anticancer, and antibiotic properties in cells, rodents, and humans. *Foods*, 5(4): 80
 20. Elkhateeb, W. A., El-Hagrassi, A. M., Fayad, W., El-Manawaty, M. A., Zaghlol, G. M., Daba, G. M. and Ahmed, E. F. (2018). Cytotoxicity and hypoglycemic effect of the Japanese Jelly mushroom *Auricularia auricula-judae*. *Chemistry Research Journal*, 3: 123–133
 21. Badalyan, S. M., Barkhudaryan, A. and Rapior, S. (2019). Recent progress in research on the pharmacological potential of mushrooms and prospects for their clinical application. *Medicinal Mushrooms*, 1 - 70
 22. Wu, T. and Xu, B. B. (2015). Antidiabetic and antioxidant activities of eight medicinal mushroom species from China. *International journal of medicinal mushrooms* 17(2), 1–10
 23. Hsu, C. H., Liao, Y. L., Lin, S. C., Hwang, K. C. and Chou, P. (2007). The mushroom *Agaricus Blazei* Murill in combination with metformin and gliclazide improves insulin resistance in type 2 diabetes: a rand-

- omized, double-blinded, and placebo-controlled clinical trial. *Journal of Alternative and Complement Medicine*, 13(1): 97–102.
24. Jeong, S., Jeong, Y., Yang, B., Islam, R., Koyyalamudi, S., Pang, G. and Song, C. H. (2010). White button mushroom (*Agaricus bisporus*) lowers blood glucose and cholesterol levels in diabetic and hypercholesterolemic rats. *Nutrition research*, 30(1): 49–56[†]
25. Niwa, A., Tajiri, T. and Higashino, H. (2011). Ipomoea batatas and Agaricus blazei ameliorate diabetic disorders with therapeutic antioxidant potential in streptozotocin-induced diabetic rats. *Journal of Clinical Biochemistry and Nutrition*, 48: 194-202.
26. Ekowati, N., Yuniati, N., Hernayanti, H. and Ratnaningtyas, N. (2018). Antidiabetic potentials of button mushroom (*Agaricus bisporus*) on alloxan-induced diabetic rats. *Biosaintifika: Journal of Biology & Biology Education*, 10(3): 655–662[†]
27. Ding, Z., Lu, Y., Lu, Z., Lv, F., Wang, Y., Bie, X. and Zhang, K. (2010). Hypoglycaemic effect of comatin, an antidiabetic substance separated from *Coprinus comatus* broth, on alloxan-induced-diabetic rats. *Food chemistry*, 121(1): 39–43[†]
28. Dotan, N., Wasser, S. P. and Mahajna, J. (2011). The culinary-medicinal mushroom *Coprinus comatus* as a natural antiandrogenic modulator. *Integrative Cancer Therapies*, 10(2): 148–159.
29. Cao, H., Qin, D., Guo, H., Cui, X., Wang, S., Wu, Y., Zheng, W., Zhong, X., Wang, H., Yu, J., Zhang, H. and Han, C. (2020). The Shaggy Ink Cap Medicinal Mushroom, *Coprinus comatus* (Agaricomycetes), a Versatile Functional Species: A Review. *International journal of medicinal mushrooms*, 22(3): 245–255.
30. Nowakowski, P., Naliwajko, S. K., Markiewicz-Żukowska, R., Borawska, M. H., Socha, K. (2020). The two faces of *Coprinus comatus*—Functional properties and potential hazards. *Phytotherapy Research*. 34(11), 2932–2944.
31. Wińska, K., Mączka, W., Gabryelska, K. and Grabarczyk, M. (2019). Mushrooms of the genus *Ganoderma* used to treat diabetes and insulin resistance. *Molecules*, 24(22): 4075[†]
32. Xiao, C., Wu, Q. P., Cai, W., Tan, J. B., Yang, X. B. and Zhang, J. M. (2012). Hypoglycemic effects of *Ganoderma lucidum* polysaccharides in type 2 diabetic mice. *Archives of Pharmacal Research*, 35(10):1793–801.
33. Rašeta, M., Popović M, Čapo I, Stiliновиć N, Vukmirović S, Milošević B, Karaman M. 2020. Antidiabetic effect of two different *Ganoderma* species tested in alloxan diabetic rats. *Rsc Advances* 10(17), 10382–10393[†]
34. Ma, H. T., Hsieh, J. F., Chen, S. T. (2015). Anti-diabetic effects of *Ganoderma lucidum*. *Phytochemistry*. 114: 109–113[†]
35. Jung, S. H., Lee, Y. S., Shim, S. H. and Lee, S. et al. (2005). Inhibitory effects of *Ganoderma applanatum* on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues. *Phytotherapy Research*, 19: 477–480.
36. Kubo, K., Aoki, H. and Nanba, H. (1994). Anti-diabetic activity present in the fruit body of *Grifola frondosa* (Maitake). I. Biological and Pharmaceutical Bulletin, 17(8): 1106–1110[†]
37. Wu, S. J., Tung, Y. J. and Ng, L. T. (2020). Anti-diabetic effects of *Grifola frondosa* bioactive compound and its related mo-

- lecular signalling pathways in palmitate-induced C2C12 cells. *Journal of Ethnopharmacology*, 260: 112962.
38. Kou, L., Du, M., Liu, P., Zhang, B., Zhang, Y., Yang, P. and Wang, X. (2019). Anti-diabetic and anti-nephritic activities of *Grifola frondosa* mycelium polysaccharides in diet-streptozotocin-induced diabetic rats via modulation on oxidative stress. *Applied biochemistry and biotechnology*. 187(1): 310 - 322.]
39. Peng, H. and Shahidi, F. (2020). Bioactive compounds and bioactive properties of chaga (*Inonotus obliquus*) mushroom: a review. *Journal of Food Bioactives*, 12: 9–75.
40. Szychowski, K. A., Skóra, B., Pomianek, T. and Gmiński J. (2021). *Inonotus obliquus* - from folk medicine to clinical use. *Journal of Traditional and Complementary Medicine*, 11: 293–302.
41. Chen, H., Lu, X., Qu, Z., Wang, Z. and Zhang, L. (2010) Glycosidase inhibitory activity and antioxidant properties of a polysaccharide from the mushroom *Inonotus obliquus*. *Journal of Food Biochemistry*, 34:178–191.
42. Wang, C., Chen, Z., Pan, Y., Gao, X. and Chen, H. (2017). Anti-diabetic effects of *Inonotus obliquus* polysaccharides-chromium (III) complex in type 2 diabetic mice and its sub-acute toxicity evaluation in normal mice. *Food and Chemical Toxicology*, 108: 498–509.
43. Sun, J. E., Ao, Z. H., Lu, Z. M., Xu, H. Y., Zhang, X. M., Dou, W. F. and Xu, Z. H. (2008). Antihyperglycemic and anti-lipid peroxidative effects of dry matter of culture broth of *Inonotus obliquus* in submerged culture on normal and alloxan-diabetes mice. *Journal of Ethnopharmacology*. 118(1): 7–13.
44. Patocka, J. (2019). Will the sulphur polypore (*Laetiporus sulphureus*) become a new functional food? *Global Journal of Medical and Clinical Case Reports*. 6 (1): 006–009.]
45. Huang, Q., Chen, L., Teng, H., Song, H., Wu, X. and Xu, M. (2015). Phenolic compounds ameliorate the glucose uptake in HepG2 cells' insulin resistance via activating AMPK. *J. Funct. Foods*, 19: 487–494.
46. Jang, J. S., Lee, J. S., Lee, J. H., Kwon, D. S., Lee, K. E., Lee, S. Y. and Hong E. K. (2010). Hispidin produced from *Phellinus linteus* protects pancreatic β -cells from damage by hydrogen peroxide. *Arch Pharm. Res.* 33, 853–861.
47. Kim, H. M., Kang, J. S., Kim, J. Y., Park, S. K., Kim, H. S., Lee, Y. J. and Han, S. B. (2010). Evaluation of antidiabetic activity of polysaccharide isolated from *Phellinus linteus* in non-obese diabetic mouse. *International Immunopharmacology*, 10(1): 72–78.]
48. Yang, K., Zhang, S., Ying, Y., Li, Y., Cai, M., Guan, R., Sun, P. (2020). Cultivated fruit body of *Phellinus baumii*: A potentially sustainable antidiabetic resource. *ACS omega*. 5(15), 8596– 8604.]
49. Bach, E. E., Costa, S. G., Oliveira, H. A., Junior, J. S., da Silva, K. M., de Marco, R. M. and Wadt, N. S. (2015). Use of polysaccharide extracted from *Tremella fuciformis* berk for control diabetes induced in rats. *Emirates Journal of Food and Agriculture*, 27(7): 585 - 591.]
50. Kiho, T., Kochi, M., Usui, S., Hirano, K., Aizawa, K. and Inakuma, T. (2001). Antidiabetic effect of an acidic polysaccharide (TAP) from *Tremella aurantia* and its deg-

- radiation product (TAP-H). *Biological and Pharmaceutical Bulletin*, 24(12): 1400–1403.
51. Chowdhury, P. and Paul, S. (2020). The Potential Role of Mushrooms in the Prevention and Treatment of Diabetes: A Review. *Journal of Biologically Active Products from Nature*, 10(5): 429–454.†
 52. Begum, N., Nasir, A., Parveen, Z., Muhammad, T., Ahmed, A., Farman, S. and Batiha, G. E. (2021). Evaluation of the Hypoglycemic Activity of *Morchella conica* by Targeting Protein Tyrosine Phosphatase 1B. *Frontiers in Pharmacology*. 12: 1148.†
 53. Dong, Y., Jing, T., Meng, Q., Liu, C., Hu, S., Ma, Y. and Teng, L. (2014). Studies on the antidiabetic activities of *Cordyceps militaris* extract in diet-streptozotocin-induced diabetic Sprague-Dawley rats. *BioMed Research International*, 1–10.†
 54. Zhang, G., Huang, Y., Bian, Y., Wong, J. H., Ng, T. B. and Wang, H. (2006). Hypoglycemic activity of the fungi *Cordyceps militaris*, *Cordyceps sinensis*, *Tricholoma mongolicum*, and *Omphalia lapidescens* in streptozotocin-induced diabetic rats. *Applied Microbiology and Biotechnology*, 72(6): 1152–1156.†
 55. Paterson, R. R. (2008). Cordyceps—a traditional Chinese medicine and another fungal therapeutic bio factory? *Phytochemistry*, 69(7): 1469–1495.†
 56. Jovanović, J. A., Mihailović, M., Uskoković, A., Grdović, N., Dinić, S. and Vidaković, M. (2021). The Effects of Major Mushroom Bioactive Compounds on Mechanisms That Control Blood Glucose Level. *Journal of Fungi*. 7(58): 1–15.